胰腺国际论坛2014资料.pptVIP

* * * * 8.5-6.7 * * * * * * * * * * Key Milestones in the Treatment of Pancreatic CancerFDA Approval for MPC1 1. Drugs@FDA.gov. /scripts/cder/drugsatfda/index.cfm. Accessed June 20, 2012. 2 MPC, metastatic pancreatic cancer, PDAC, pancreatic ductal adenocarcinoma. 2014NCCN指南推荐：晚期胰腺癌一线治疗 分享内容 思考一、化疗方案，孰优孰劣 思考二、预后因素深度分析 思考三、支持治疗，被动？积极？ 思考一、化疗方案，孰优孰劣？ 生存期比较 方案 PFS OS DCR 5-FU 2.5 4.41 35 Gem 3.55 5.65 49.2 S1 3.8 9.7 Gem+特罗凯 3.75 6.24 57.5 Gem+nab-Pac 5.5 8.5 48（33%） Folfirinox 6.4 11.1 70.2 GS 5.7 10.1 晚期胰腺癌专家推荐或者NCCN指南： a For fit patients defined as those with ECOG PS 0/1, 75 years old, no